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INTRODUCTION TO THE THESIS 
Delirium is an important syndrome associated with poor outcomes for patients, carers and 
staff. The incidence and prevalence of delirium in people with cancer admitted to hospital is 
not established. The few studies from the in-patient cancer setting, report wide-ranging 
incidence and prevalence rates, and other studies report rates for oncology patients, these 
data relate to in-patient palliative care or subsets of aged care cohorts for whom there is a 
known cancer diagnosis. Similarly, some data exist relating to reversibility of delirium in 
people with cancer, particularly towards the end of life; but not a great deal is known about 
reversibility in the acute, in-patient oncology setting. Delirium detection is critical for 
treatment, however the use and effectiveness of bedside screening tools for delirium 
detection is not well established for in-patient oncology settings. The aim of this thesis was 
first to understand in more detail the literature relating to the epidemiology of delirium in the 
acute in-patient oncology setting, and second to test a novel delirium screening tool in 
comparison to a diagnostic reference standard. 
 
For the purpose of this thesis “delirium detection” is a general term applied to the 
identification of delirium using a screening tool, diagnostic tool or reference standard, or a 
clinical case of delirium. Screening is defined as the testing of a person or group of people 
for the presence of a disease or other condition. {Oxford Dictionaries 
https://en.oxforddictionaries.com/definition/screening} A screening test is defined as a 
simple test performed on a large number of people to identify those who have or are likely to 
develop a specified disease. {dictionary.com https://www.dictionary.com/browse/screening-
test?s=t} The Diagnostic and Statistical Manual of Mental Disorders Manual fifth edition 
(DSM 5) is used to define delirium. A diagnostic reference standard is defined as an 
evaluation by an independent reference rater, using an accepted standardised, reproducible 
diagnostic system.   
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Three sub settings relevant to the overall setting of adult oncology inpatients (or acute 
oncology in-patient setting) are investigated. Our particular setting or “target setting” 
describes the population of patients in an acute hospital or comprehensive cancer centre, 
with the diagnosis of cancer under the care of a medical oncologist, radiation oncologist or 
palliative care physician, on a ward where the management of cancer and the complications 
of treatment is the focus of care. Surgical oncology, and intensive care settings have been 
intentionally excluded. Subsets patients with cancer diagnosis within aged care cohorts 
were, included in the index setting. Our overall target setting was chosen as it has relevance 
to improving clinical care provided to this group of patients with cancer, cared for in the in-
patient setting. 
 
The first chapter is a scoping review of the literature relating to incidence, prevalence and 
reversibility of delirium in the index setting. Following application of inclusion and exclusion 
criteria, twelve studies were identified. In addition, this review sought to determine which 
delirium screening tools and which reference standards were used as the basis of case 
ascertainment to underpin epidemiological studies. Critical appraisal of methodological 
constraints of the studies was considered and the implications for knowledge gaps were 
identified. 
 
The second chapter reports findings from an original study investigating the clinical utility of 
the Single Question in Delirium (SQiD), a novel tool which was previously developed by the 
author. The methodological approach compared the SQiD against clinical review by 
consultant liaison psychiatrists in admitted, oncology patients. Considering the constraints 
of the acute oncology setting, the clinical utility of the SQiD was compared with the short 
version of the Confusion Assessment Method (CAM) in parallel. The primary aim was to 
determine the Negative Predictive Value (NPV) of the SQiD compared with psychiatrist 
assessment and secondarily we aimed to determine agreement between the diagnostic 
standard (psychiatric assessment) and the SQiD. The negative predictive value of the CAM 
was also compared with the SQiD. In our study the short CAM is used as a comparator 
vi 
clinical screening tool, not as a diagnostic standard. This provided comparison with an 
established short delirium bedside tool. 
 
This thesis provides a synthesis of knowledge to date relating to the epidemiology of 
delirium in admitted cancer patients and tests a short pragmatic delirium screening tool 
against a diagnostic reference standard. It contributes to the knowledge base relating to 
delirium in cancer patients admitted in the acute setting and is hypothesis generating for 
future research.  
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CHAPTER 1. SCOPING REVIEW OF DELIRIUM IN CANCER INPATIENTS 
What is known about delirium incidence, prevalence, reversibility in the 
oncology, acute in-patient setting? Which tools have been used for delirium 
screening and what reference standards have been used in epidemiological 
studies? 
 
1.1.0 ABSTRACT  
BACKGROUND: Delirium is an important syndrome associated with poor 
outcomes for patients and their carers, with negative impacts on staff. The 
literature provides epidemiological data on incidence, prevalence and 
reversibility in many health populations, and bed-side screening tests have 
been validated in various clinical settings, but there has been limited 
representation of hospitalised cancer patients in these studies to date.  
OBJECTIVES: The target population was admitted, adult, oncology patients 
in an acute-hospital or comprehensive cancer centre. The research 
questions were: 1. Which instruments are most commonly used to detect 
delirium? 2. Which reference standards have been used to measure rates of 
delirium? 3. What is the incidence and/or prevalence of delirium in this 
setting? and 4. What is the rate of reversibility of delirium in this setting?  
METHODS: MEDLINE, EMBASE, CINAHL, PsycINFO, and SCOPUS 
databases were searched from January 1st, 1996 to August 12th, 2017. 
Delirium, cancer, in-patient oncology and delirium detection/screening were 
the four key concepts for the search. On the basis of study criteria, hand 
search articles plus database search returns were included in title and 
abstract screening, followed by full text review. Risk of bias in seven scoping 
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domains was rated according to Quality Assessment of Diagnostic Accuracy 
Studies (QUADAS) criteria. 
RESULTS & DATA SYNTHESIS: Combined searches returned 896 unique 
studies; 91 were retained for full text review.  Twelve studies were eligible for 
final data abstraction and synthesis. Four delirium screening tools and one 
cognitive algorithm were used as reference standards. Two studies 
presented delirium incidence rates; 7.8% (unscheduled admissions), and 
17% respectively. Prevalence rates ranged from 18% to 33% for general 
medical or oncology wards (3 studies); 42% to 58% for Acute Palliative Care 
Units (APCU) (4 studies); and in the setting of older cancer patients: 22% and 
57% (2 studies). Three studies, in two settings, reported reversibility; 26% 
and 49% respectively (both APCU) and 30% (older patients with cancer). 
Two of the twelve studies were rated as low risk of bias according to 
QUADAS criteria. Tool selection, study flow and recruitment bias decreased 
study quality. 
CONCLUSION: There are a low number of studies evaluating delirium in 
adult oncology patients. Our review has identified important knowledge 
gaps. We recommend our findings are used in conjunction with existing 
evidence, to inform methodology in future studies with regard to optimal 
selection of delirium screening tools, diagnostic reference standards and that 
particular attention is paid to case ascertainment methods when reporting 
rates of delirium and delirium reversibility. A clear distinction between these 
two functions and, is essential to closing gaps in knowledge relating to the 
epidemiology of delirium in this population, including incidence, prevalence 
and reversibility. 
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1.2.0 BACKGROUND AND AIM 
Delirium is a neurocognitive syndrome characterised by altered level of 
consciousness, altered awareness and an impaired ability to fix and focus, 
and/or shift attention. It is common in hospitalised patients and distinct from 
other causes of cognitive impairment. Delirium has acute onset, a fluctuating 
course, and evidence of an underlying physiological cause. Diagnostic and 
Statistical Manual of Mental Disorders Manual fifth edition (DSM 5) describe 
five criteria and in addition to the characteristics above, include disturbed 
motor function and cognition in the following domains: memory, orientation, 
language, and perceptual distortion.[2]  in addition, critique of the current 
DSM 5 definition include concerns about the absence of criteria for level of 
arousal, however on the whole DSM 5 represents the characteristics of 
syndromic delirium more accurately than previous DSM iterations.[3] 
 
Studies in various settings have demonstrated that delirium is preventable,[4] 
screening tools are effective,[5] and delirium is often reversible [6]. Delirium is 
associated with serious adverse outcomes, including increased morbidity 
and mortality, longer length of stay [7, 8] as well as marked distress for 
cancer patients, their families and staff [9, 10].  
 
A number of studies informing our understanding of delirium in cancer 
patients exist in the literature. Few of these are focused on all adults in an 
acute-hospital, oncology, in-patient setting[11-13] and for the most part, 
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palliative care has been the setting for studies of delirium for cancer patients. 
Many studies of delirium in patients admitted to acute-hospitals report 
findings from cohorts targeting patients over 65 years of age [14] or focus on 
perioperative settings including intensive care units (ICU), or the emergency 
department [15, 16]. Studies relating to cancer patients in “stand-alone” 
palliative care units, or subsets of cancer in-patient cohorts on the basis of 
referral to palliative care [17, 18] or psychiatry consultation [19] services in 
acute hospitals, are more common. 
 
Misdiagnosis of delirium is an important issue in clinical settings,[19] and can 
contribute to poor outcomes for patients, carers and staff. Outcomes may be 
even worse if the diagnosis of delirium is delayed or missed entirely. Studies 
of patients in general hospitals indicate that pain, younger age, correct 
orientation in person, place and time, and previous psychiatric diagnosis 
(especially bipolar disorder or psychosis) are important risk factors for the 
diagnosis of delirium being missed.[20] Three studies focused on patients 
with cancer referred to consultation psychiatry services report misdiagnosis 
of neuropsychiatric conditions, with two studies reporting 46% and a further 
one reporting 63% of missed diagnosis of delirium.[19-21]. Risk factors in 
the inpatient oncology setting have been identified, one study found higher 
age, poor performance on cognitive testing and lower serum albumin to be 
associated with higher risk of delirium.[22] 
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The scoping review methodology was chosen as delirium is a complex 
concept and preliminary literature searches indicated a low number of 
studies relating to the target population (oncology inpatients in oncology 
wards of acute hospitals or comprehensive cancer care centres) as well as 
heterogeneity across studies. The scoping review methodology allowed 
mapping of the existing knowledge and identification of knowledge gaps.  It 
allowed methodical examination of the topic with a broader perspective in 
order to provide a foundation for future work.   
While it is usual for a scoping review to include all evidence of varying 
quality, and often not to assess the quality of the studies, we felt adding a 
quality assessment provided important information on emerging evidence 
that may be useful in terms of informing future work. 
 
Understanding the knowledge-base in relation to delirium in cancer patients 
is the first step towards improved patient outcomes for this group. 
Epidemiological studies of delirium in the index population, that is all adult 
admitted oncology patients, are few therefore a scoping review methodology 
was adopted to systematically map evidence relating to our research 
questions. [23]  The aim of this review is to synthesise knowledge and 
identify gaps relating to the selection of detection instrument, incidence, 
prevalence and reversibility of delirium in hospitalised, adult patients with 
cancer.  
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1.3.0 METHODS  
The target population was admitted, adult, oncology patients in an acute-
hospital or comprehensive cancer centre. The research questions were:  
1. Which screening instruments are most commonly used to detect delirium?  
2. Which reference standards have been used to measure rates of delirium?  
3. What is the incidence and/or prevalence of delirium in this setting? and  
4. What is the rate of reversibility of delirium in this setting?  
 
The search strategy was centred on four key domains; delirium, cancer, 
inpatient oncology and delirium detection/screening.  
Major eligibility criteria included cancer diagnosis, admission to an acute 
hospital ward and assessment of delirium with an objective tool or 
reproducible method. Full inclusion and exclusion criteria are presented in 
Box 1. Studies recruiting subsets of the admitted oncology population, such 
as those exclusively targeting oncology patients referred for psychiatrist or 
palliative care consultation, and studies with a focus on perioperative or ICU 
settings, were excluded. Studies focused on elderly patients were included 
only if results for oncology patients enabled independent abstraction of data 
relating to the cancer cohort.  
7 
Box 1. Scoping review inclusion and exclusion criteria. 
INCLUSION CRITERIA 
1. Original study 
2. Focus of the paper is delirium specifically (e.g. not confusion, cognitive 
impairment, acute brain syndrome)  
3. Oncology Setting – focus of the paper is adults in the oncology setting. Target 
setting is oncology ward in acute hospitals including tertiary referral and cancer 
centres.  Emergency departments accepted if focus is oncology and patient is 
admitted. Acceptable if oncology population can be abstracted from broader 
study (e.g. hospital wide point prevalence, subset of cancer patients within an 
index population of older patients with cancer).  
4. Palliative care patients if in-patient or combined oncology or palliative care 
setting for example in a comprehensive cancer centre, but not palliative care 
patients in a “stand alone” inpatient unit or hospice. 
5. Must include delirium assessment with an objective tool, or clinical diagnostic 
criteria  
6. Human  
7. English language  
 
EXCLUSION CRITERIA 
1. Not exclusively haematology setting or non-solid tumours (haematological 
malignancy). Will accept haematological oncology diagnoses as long as not 
exclusively haematological malignancy cohort. 
2. Not exclusively non-oncology palliative care, will accept if minority of non-cancer 
palliative care patients included as long as oncology parameters fulfilled.  
3. Not exclusively post-operative or operative surgical setting including surgical 
oncology 
4. Not exclusively alcohol withdrawal 
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The search strategy was developed in consultation with an academic liaison-
librarian and research supervisors. Combinations of key words and medical 
sub-headings (MeSH) were tested and refined using preliminary MEDLINE 
searches. Initial returns were reviewed by the author, research supervisors, 
the librarian and research assistant, and a final list of terms was determined. 
MEDLINE, CINAHL, PsycINFO, EMBASE and SCOPUS databases were 
divided between two independent reviewers (the author and a research 
assistant) and searched according to our strategy. Publication date was 
limited from 1st of January 1996 to 12th of August 2017. A full list of key 
words, MeSH headings and returns for individual databases are shown in 
Appendix 1.  The search was supplemented by articles identified from the 
primary author’s prior knowledge of the literature and assessed against study 
criteria to confirm inclusion. For pragmatic reasons screening of the hand-
search papers was held over until title and abstract screening. Duplicates 
were removed. 
 
Identified articles from combined search returns were downloaded to 
EndNote (version X8). Duplicates were removed within the EndNote using 
the find duplicates function imported using COVIDENCE.[24] Title and 
abstract screening plus full text review was conducted independently by the 
author and a research assistant (MBS and IW). Conflicting assessments on 
title and abstract review and full text review were discussed and a 
determination regarding study inclusion or exclusion was made by 
consensus. Research supervisors provided feedback on the final inclusion 
criteria which was used to determine which studies progressed to data 
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abstraction.  Citation data were exported from COVIDENCE software and a 
comma separated value (CVS) spreadsheet, detailing patient setting, study 
characteristics, and information relating to our four research questions, was 
generated. Data abstraction was carried out by the author and research 
assistant independently, and then cross checked by these two reviewers for 
transcription errors. In studies where the same data were reported in several 
papers, we took the earliest paper fitting our inclusion and exclusion criteria 
as the index study; however additional information available in related or 
subsequent papers was extracted and presented alongside the index study 
where possible.[6, 25-29] Quality considerations and information synthesis 
was undertaken by the author with feedback from research supervisors and 
research assistant. In-depth quality assessment was not possible due to 
study heterogeneity but sources of bias and generalisability were assessed 
using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) 
system to evaluate patient selection, index tool, reference standard and 
study flow and timing.[30] Reporting of pooled data relating to the  four 
research questions was not anticipated due to the low number of eligible 
studies and heterogeneity of included studies. 
For the purposes of the study, a delirium reference standard was defined as 
a diagnostic assignment tool such as World Health Organization (WHO) 
International Classification of Diseases, 10th Revision (ICD-10) or the 
American Psychiatric Association Diagnostic and Statistical Manual of 
Mental Disorders (DSM) criteria, applied by a psychiatrist or consultant 
physician. The Confusion Assessment Method (CAM) was included as a 
reference standard for case ascertainment for the purposes of this review, 
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only if reference-rater training in use of the CAM was explicitly-stated.[31] 
This follows published recommendations for valid use of the CAM [31] as 
well as diagnostic assignment in delirium research [1]. 
 
1.4.0  RESULTS 
1.4.1 Search Results  
Target databases were searched on 12 August 2017 by MBS and IW. 
Returns were as follows: Medline (211), EMBASE (684), SCOPUS (97), 
PsycINFO (52) and CINAHL (47). A total of 805 unique papers were 
identified.  Hand search added 91 new titles, increasing total studies for 
review to 896. Following review of the titles and abstracts according to the 
eligibility criteria, 91 studies were included in full text review, after which 12 
studies remained for data abstraction and synthesis.  Figure 1.1 shows 
results and flow of the literature search.   
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Figure 1.1 Flow diagram of literature search 
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1.4.2 Characteristics of included studies 
Recruitment periods for the included studies ranged from 1997 to 2015, with five of 
the studies relating to hospital admissions prior to 2010. Study design of all 12 
studies was observational: six were prospective, six were retrospective. Two studies 
were secondary analyses of data from prior prospective studies. Studies were 
grouped into three categories on the basis of the clinical setting: 1. in-patient, acute-
hospital or comprehensive cancer centre oncology ward; 2. older oncology patients 
(patients > 65 years, admitted to acute hospitals under any admitting team, with 
cancer as the primary diagnosis or co-morbidity); and 3. palliative care ward in 
acute-hospital or comprehensive cancer centre (APCU). The rationale for this 
grouping was based in the observation that clinical care for oncology patients occurs 
largely in one of these three settings, but that from the point of view of research, 
these settings tend to be studied independently. We wanted to understand the use 
of delirium detection tools across the spectrum of admitted adult patients with 
cancer in order to improve care in this cohort.  
 
Five studies [22, 26, 32-34] were in the adult-oncology sub-setting. Three of these 
approached all patients on nominated days [32-34], while two studies stated all 
admitted patients were approached[22, 35]. Three studies were of older cancer 
patients.[27, 36, 37] One of these was a point prevalence study in which patients 
over 65 years were recruited from more than 100 Italian hospitals across several 
regions during one 24hr period.[36] Unpublished subset data on patients in this last 
cohort, was provided by the author via personal communication.[38] A further study 
recruited all patients aged 65 years or older admitted to the general medicine or 
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oncology ward in two Dutch teaching hospitals.[37] The remaining study in the older 
cancer setting was a secondary analysis of a subset of cancer patients from a 
previous study, composed of patients from three North American centres.[27] Four 
studies [6, 39-41] were in an APCU. Three of these [39-41] were retrospective 
studies from the same North American treatment centre, over distinct study periods.  
Tables 1.1 and 1.2 provide detailed data for the included studies related to the 
research questions of interest, including patient population, study purpose, patient 
and disease demographics, and method of participant recruitment. Table 1.3 
summarises quality considerations according to QUADAS criteria.[30] 
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Table 1.1  Study Design and Setting 
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Table 1.2   Patient Characteristics, Study Tools and Delirium Rates 
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Table 1.3  Quality assessment using QUADAS tool 
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1.4.3 Patient recruitment and demographics 
Patient characteristics were described in varying detail; four studies[6, 22, 
25, 32] specified histological diagnosis of cancer and three specified 
consecutive recruitment.[29, 36, 39] Four studies gave detailed description 
of recruitment and seven provided the number of eligible patients when 
providing number of participants. Eight studies[6, 22, 26, 33, 34, 39-41] 
presented flow diagrams or data accounting for eligible patients not included 
in recruitment or analysis. 
 
Two of the 12 studies in the review had less than 100 participants, and one 
of these was a feasibility study with 19 patients [34]. In relation to patient 
characteristics, 10 of 12 studies reported primary cancer types. All reported 
age; the average of the mean age (years) in each setting were as follows: 
oncology 59, older cancer 78, and APCU 60. 
In total, six studies reported length of hospital stay [22, 27, 33, 37, 40, 41]; 
these were reported as mean or median, and ranged from 3-9.8 days. 
Clinical information describing cancer stage, co-morbidity burden, overall 
illness severity, performance status and/or vital status at discharge, were not 
uniformly described. Only one of five studies in the adult oncology setting 
[33] provided detailed information that described markers of burden of 
disease. Five of 12 studies across all setting subgroups  reported stage of 
cancer in terms of metastatic versus loco-regional disease.[6, 33, 35, 40, 42] 
One study reported the number of patients receiving anti-cancer 
treatment.[37] One made the statement “patients with cancer who had 
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complications to their active treatment or complications to their cancer were 
admitted to this ward”.[32] Another provided narrative descriptive 
information regarding the study sample as follows:  
“patients are admitted to the APCU when there is severe symptom distress 
… and those who are transitioning to end-of-life care. In most cases, 
patients have discontinued active therapy at the moment of admission to the 
APCU.”[39]    
 
There was no common basis for reporting population characteristics in terms 
of co-morbidities, illness severity or functional impact. One study reported 
vital status at discharge and European Co-operative Oncology Group 
performance status (ECOG) [42], two studies reported Charlson co-morbidity 
index [43], one also presented Katz’ activities of daily living (ADL) [44], and 
one presented acute physiology and chronic health evaluation II (APACHE II) 
scores [45].  
 
1.4.4 Scoping questions; data relating to our four research questions 
1.  Which instruments are most commonly used to detect delirium?  
A total of five previously validated delirium screening tools were used for 
clinical identification of delirium: Nursing Delirium Screening scale (Nu-
DESC, n=1); Delirium Observational Screening Scale (DOSS, n=1); four A’s 
test (4AT, n=1); Neelon and Champagne (NEECHAM, n=1); and, Memorial 
Delirium Assessment Scale (MDAS, n=4). One study tested a novel delirium 
screening tool (Single Question in Delirium; SQiD and one tested existing 
cognitive measures (Clock Drawing Test, Mini Cognitive, Digit Span Test) 
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against a reference standard.  Six studies included a second delirium 
screening tool, as presented in Table 1.2.  
2. Which reference standards have been used to measure rates of 
delirium?  
Across the 12 eligible studies, nine methods for determining cases of 
delirium (or caseness) were described.  The criteria used to identify delirium 
were as follows: MDAS (n=4); CAM (n=3); DOSS (n=1); ICD 10 (n=1); DSM IV 
(n=1); 4AT (n=1); NEECHAM (n=1); Nu-DESC (n=1), a battery of tests of 
cognition (n=1). Four of twelve included studies used an accepted reference 
standard [1] for case ascertainment. Two studies in the adult oncology 
setting used diagnostic criteria, namely the ICD 10 [32] (the assessor was not 
stated), and DSM IV/IVR (assessed by final year psychiatry fellow or 
psychiatrist) [34]. The CAM, incorporated as part of an interview by a 
psychiatrist, was used as a reference standard in one study.[22] Another 
study used the CAM as part of a review by a multidisciplinary gerontology 
team as the delirium reference standard [37].  A further study used the CAM 
as well as ICD 10 criteria as part of a structured review by a psychiatrist as 
their reference standard [32].  Assessor training for CAM was reported in  
two out of three studies using the CAM as a reference standard [22, 26]. 
Contrary to evidence based-recommendations, neither of the two studies 
using the CAM as a delirium screening tool specified assessor training [32, 
34]. 
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Seven studies used screening tools as the basis of identifying delirium 
caseness. Of the prospective studies, Bellelli et al used the 4AT assessed by 
the attending physician [36]; Lawlor et al used DSM IV to confirm 
participants who had Mini-Mental State Exam (MMSE) scores above a cut-
off point on first line testing [6]; and Gaudreau et al used the Nu-DESC, 
applied by trained bedside nurses familiar with the tool [35]. Of the 
retrospective studies, Neefjes et al used the DOS applied by trained bedside 
nurses familiar with the tool [33], and three studies used the MDAS with a cut 
off to identify from chart review[39-41]. The area under the curve (AUC) of 
MDAS was one of several secondary outcomes reported by the Gaudreau et 
al study (AUC 0.823), using a cut off score of >6.[35] 
3. What is the incidence and/or prevalence of delirium in this 
setting? 
Rates of delirium incidence and prevalence reported by studies in this review 
are presented in Table 1.2 These data are considered in the context of their 
specific patient sub-populations. However, given the heterogeneity among 
studies reviewed, combining rates of incidence or prevalence was not 
possible, therefore data regarding incidence and prevalence are presented 
separately.  
 
Amongst the adult medical oncology studies, Neefjes et al found an 
incidence of 3.5% of all admissions or 7.8% of unscheduled admissions [33], 
and Gaudreau et al found an incidence of 16.5% [35]. Three studies in this 
sub-setting presented prevalence data; 18% [22], 27% [34], and 33% [32] 
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respectively.  In the APCU sub-population, prevalence rates of 42% [6], 43% 
[40], 48% [41] and 58% [39] were reported. The three studies of older cancer 
patients reported prevalence rates of 19.2% [36], 21.5% [37], and 57% [27] 
respectively. One study in the oncology sub-setting [33], and one in the 
APCU sub-setting [39], reported the frequency of delirium subtypes: 
hyperactive 11/52 (21%) and 61/245 (25%), hypoactive 20/52 (38%) and 
73/245 (30%), mixed 18/52 (35%) and 112/245 (46%), and not known 3/52 
(6%) and 77/245 (31%) respectively. 
4.  What is the rate of reversibility of delirium in this setting? 
Although defined in different ways in different studies, delirium reversibility 
was reported in three studies, two of these were in APCU settings; 46/94 
(49%) [6], 68/229 (26%) [39],  and one in older patients with cancer 13/43 
(30%) [28]. 
 
1.5.0 DISCUSSION 
This scoping review has identified significant gaps in knowledge about the 
epidemiological characteristics of delirium in acute oncology populations. In 
relation to our scoping questions, a variety of delirium detection tools were 
identified, but few studies used accepted diagnostic or reference standards 
for case ascertainment in calculating the incidence or prevalence data 
reported. Sources of bias included, study design which relied on initial 
screening with a tool that may have excluded delirious patients and 
inappropriate case ascertainment. Generalisability of findings was reduced 
by limited description of patient characteristics. All studies reported delirium 
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incidence and/or prevalence however study heterogeneity limited further 
analysis. A small number of eligible studies reported reversibility of delirium. 
Limitations to our review include the small number of studies and small or 
moderate sample sizes of all but one study. Nevertheless, our findings help 
to consolidate what is known about the four scoping questions, and a lack of 
data relating to all four has been identified. Given the clinical importance of 
the scoping questions, it would be appropriate for these gaps to be 
considered in relation to the methodology of future studies.  
 
1.5.1 Grouping of studies 
The following is noted in relation to the three sub-settings included in our 
review. In addition to patients admitted under the care of a medical 
oncologist or radiation oncologist, patients under the direct care of palliative 
care physicians, or on palliative care wards in acute hospital or cancer 
centres were included in this review. The rationale for this is that, in terms of 
disease and symptom burden, characteristics of patients under the care of 
an oncologist and those under the care of a palliative care physician, exist on 
a spectrum and are not two dichotomous categories. This makes sense in 
terms of contemporary models of care which situate the provision of 
palliative care (symptom management, care planning and family support as 
well as care at the very end of life) alongside, rather than at the conclusion, 
of anti-cancer treatment [46, 47]. This approach contributes to a continuum 
of patient characteristics across palliative care and medical oncology 
admitting teams in the acute hospital setting. Furthermore anti-cancer 
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treatments are generally delivered in the outpatient setting and admitted 
oncology patients therefore tend to have a higher overall symptom burden 
compared to non-admitted cancer patients.  
 
The overlap of characteristics of these groups of patients is illustrated by the 
following two studies. The first is a review of approximately 700 oncology 
ward admissions which found that 74% of admissions were urgent and 80% 
were due to uncontrolled symptoms. Despite this, the majority of the 
hospitalisations resulted in discharge home (61%); in 26.5% the patient died 
during the index admission and in 11% the patient was transferred to a 
hospice.[48] The second study was carried out in an APCU setting and found 
134 of 166 patients (80.7%) were discharged alive, while 32 (19.3%) died 
during the index admission.[40]  
 
Given the importance of delirium in aged care settings, the identification in 
this review of studies which focused on delirium in older patients with cancer 
was not unexpected.[22] Increasingly the relevance of appropriate 
management of older patients with cancer has been recognised, highlighting 
the importance of understanding the epidemiology of symptoms such as 
delirium in older cancer patients.[49]  
 
1.5.2 Inter-relationship of delirium Risk Factors 
Delirium is a multifactorial syndrome, in terms of baseline risk as well as 
precipitating/aetiological factors; the relationship of delirium risk with 
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demographic factors such as age and clinical factors, such as a cancer, is 
complex. Consequently, analysing delirium risk and describing 
epidemiological characteristics of the cancer population with delirium is also 
complex and in particular, the interplay of age, cancer diagnosis and multi-
morbidity is important but not straightforward. Cancer is not a single disease 
and heterogeneity in relation to type, stage, physiological impact and 
symptom profile, contributes to difficulty in determining which factors are the 
most critical drivers of delirium or the relative contribution of these factors, 
and what are the key differences between cancer and non-cancer patients in 
relation to risk of delirium.  
 
One of the studies in the older cancer sub-group provided comparative 
figures of delirium point prevalence in cancer and non-cancer patients; 
19.2% (n=323) for patients with cancer compared to 23.9% (n=1544) of the 
patients with no cancer diagnosis (p=0.06). [36] Multiple delirium risk factors 
such as co-morbidities, presence of physiological disturbance and 
medication burden are factors that seem to be universal in understanding 
overall delirium risk.  Although this was outside the scope of this particular 
study, analysis of risk factors and their influence on the incidence of delirium 
in older, hospitalised cancer patients is warranted. 
 
1.5.3  Delirium screening tools 
There are many delirium screening tools developed for and/or validated in 
various populations, predominantly in hospitalised patients, and these have 
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been reviewed elsewhere.[15, 16, 50-52] Several screening tools such as the 
CAM, Nu-DESC and 4AT have been validated in in-patient palliative care 
settings.[26, 53, 54] To our knowledge, the tools for which psychometric 
properties have been assessed in hospitalised cancer patients in the acute 
setting, are the Nu-DESC and MDAS.[26, 29, 55]  There is a clear rationale 
for use of the Nu-DESC as a delirium screening tool, where initial validity was 
measured against the CAM as applied by a research nurse or 
psychiatrist.[26]  
 
The 4AT has been tested in “stand-alone” palliative care, in-patient settings 
[54] and in older in-patient settings.[56, 57] . It is not unreasonable to 
extrapolate from validation of the 4AT in the general hospital population to 
the oncology in-patient setting however publications in relation to the use of 
the 4AT in the setting of hospitalised patients with cancer is limited to an 
unpublished subset evaluating point prevalence of delirium in older 
patients.[38] With the use of the 4AT in ongoing, epidemiological studies, 
interest in the 4AT in specific populations such as in-patient oncology, may 
increase  
 
The Confusion Assessment Method [31] (CAM) is a well-established tool for 
delirium detection. While the CAM, in various forms, has been successfully 
tested for clinical use as a delirium screening tool, with rigorous adherence 
to administration protocol, it may also be appropriately used as a diagnostic 
tool or reference standard. There are several CAM versions, such as the long 
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CAM, the short CAM and CAM-ICU [58]. Validation of the CAM has occurred 
in older patients in various settings and the long CAM has been 
predominantly tested for delirium screening in inpatient hospice 
populations.[53, 58] Although the CAM has not been validated as a delirium 
screening tool in acute oncology settings specifically, it is reasonable to 
extrapolate from other acute care settings and its use in advanced cancer 
patients in inpatient hospice settings. With adherence to stringent training, 
the CAM has well established psychometric properties and the rigorous 
application of this diagnostic algorithm as a research standard is well 
supported.[16] However, achievement of its potential for diagnostic 
assignment is dependent on adherence to training and our review found that 
in the eligible studies, although the CAM was used by highly skilled 
clinicians, assessor training was not well described.[22, 32, 34, 37] Explicit 
description of training is advisable for future studies utilising the CAM for 
case ascertainment.  
 
Four of the twelve included studies used the MDAS[6, 39-41]; in two studies 
it was used for case ascertainment using a cut-off score [40, 41]. A third 
study used the MDAS for severity rating only.[6] Many authors describe the 
MDAS as a tool designed specifically to rate delirium severity, but there is a 
lack of evidence for its use as a delirium screening or diagnostic (case 
ascertainment) tool[16]. One reason the use of the MDAS for case 
ascertainment is not supported, is that it identifies symptoms of delirium but 
its structure does not reflect the syndromic nature of delirium necessary for 
diagnostic assignment. Using the MDAS with a cut off score to identify 
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delirium, regardless of the cut off specified, may therefore risk false positive 
results as patients with delirium symptoms who do not fit the core diagnostic 
criteria for delirium may be labelled case positive. Several studies in this 
review used the MDAS alone, which may bias reported delirium detection 
rates. [16, 41]  
 
Conceived as a cognitive assessment tool for dementia screening the MMSE 
has been found to have poor performance as a bedside tool for identifying 
delirium. [59, 60]Using a cut off score of 24/30 in an aged care setting a 
likelihood ratio of 1.6 for true case identification has been calculated making 
it a poor choice for delirium case finding.[16] Further, use of this tool as an 
initial screening test for delirium risks inclusion bias, decreasing the accuracy 
of incidence and prevalence rates derived from inclusion based on the 
MMSE.  
 
1.5.4 Distinguishing between delirium screening instruments, 
reference standards and establishing diagnostic assignment 
In regard to the studies included in this review, clinical considerations 
appeared to be the major driver of choice of delirium detection tool, both in 
the retrospective and prospective studies. Given the need to choose clinical 
tools to suit the context of use, some heterogeneity across detection tools 
was expected. Tool selection is also an important consideration in terms of 
translation of research findings, and pragmatic choices that translate to real 
world clinical settings are important. Adherence to methodologies 
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supporting accurate and reproducible delirium diagnosis is however, 
required of a reference standard when testing the validity of a delirium 
screening tool, or establishing incidence and prevalence.[1] For the latter 
purpose, a diagnostic reference standard (rather than a screening tool) will 
give more accurate information and studies using screening tools for the 
purpose of determining epidemiologic information such as incidence or 
prevalence, must be evaluated in context. Inappropriate choice of tool for the 
study design, especially where diagnostic ascertainment was required, as 
well as a blurring of the distinction between screening tools and diagnostic 
reference standards, and lack of reporting of reference-rater training was an 
important finding. Study flow and retrospective methodology also 
contributed to potential bias in case ascertainment.  
 
1.5.5 Delirium Incidence and Prevalence  
Reported rates of delirium incidence and prevalence varied across the three 
settings. In APCUs delirium rates were higher than those in oncology in-
patients. However, the methodological issues discussed above are critical 
issues. For example, the lower rates (7.8% for non-elective admissions) 
found in one study [33] could be the effect of missed cases due to reliance 
on clinical detection for study inclusion or may reflect a true difference. 
Similarly, it is not possible to determine if the higher rates of delirium 
reported in the APCUs represents a true incidence and prevalence, or if they 
are due to the retrospective study design, choice of delirium detection tool. 
It is also possible that the criteria for delirium caseness may have been more 
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inclusive due to high sensitivity and low specificity of the study tool. The use 
of the MDAS may have contributed to inflated delirium rates in those studies 
due to its inability to detect syndromic delirium. One prospective study from 
the APCU setting [6] did use consecutive recruitment and reported numbers 
of eligible versus included patients. However, initial inclusion was based on 
MMSE screening which as described above, risks ascertainment bias.   
 
In the older cancer patient cohorts included in this review, differences in 
delirium incidence and prevalence might be accounted for by study 
heterogeneity and differences in patient recruitment. For example, in the 
Bellelli[36] and Hamaker[37] studies, point prevalence of 62/323 (19.2%) and 
prevalence of 61/283 (21.5%) was found for consecutively recruited patients, 
with the reference standard applied to all eligible patients. Both these studies 
reported similar co-existing dementia rates of around 15%, and Charlson 
Co-morbidity (CCM) index scores of 5.3 and 1.1 respectively (scale can 
range from 0 to 31).  
 
1.5.6 Delirium reversibility 
It was not possible to compare delirium reversibility across the different 
studies. Of four studies reporting reversibility [6, 27, 39, 40], two [6, 27] did 
not explicitly state how reversal was defined; one used the MDAS or clinical 
documentation to determine delirium reversibility and another used a MDAS 
cut off score at day 5[40]. These data may be constrained by retrospective 
methodology, the absence of a diagnostic reference standard, and/or study 
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flow reliant on clinical documentation. Reversibility is an important patient 
related outcome; but requires prospective, longitudinal study design, use of 
a robust diagnostic standard and explicit definition of delirium reversal. 
Assessment of delirium reversibility is an important issue for consideration in 
design of future studies. 
 
1.5.7 Source of Bias 
Methodology of included studies was assessed using QUADAS criteria.[30] 
In the studies included, patient selection, choice of delirium screening tool 
and the choice of diagnostic reference standard, were all identified as a 
source of bias. Issues relating to recruitment flow were also important 
considerations. For example, patient selection methods at times risked 
exclusion of potentially delirious patients due to retrospective design, 
convenience sampling, and ascertainment bias. 
 
1.5.8  Reproducibility and Generalisability of findings 
Several issues relate to generalisability of study findings. First, determining 
the true rate for a given in-patient population (which is likely to be 
heterogeneous), and second, determining the true delirium rate for a given 
cancer type/stage. These patient characteristics were not uniformly reported 
in the included studies. We found the included studies were not designed to 
adequately answer either of these questions. In order to determine the 
delirium rate in a particular setting, a consecutive cohort is required for a 
specific oncology population.  Information relating to staging and treatment 
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in order to establish disease burden and other risk factors for delirium in this 
population is also an important consideration for future studies.[22]   
 
1.5.9  Describing patient characteristics 
Studies had various approaches to describing populations. The CCM index 
or APACHEII were used by several studies and on face value should 
describe burden of disease within the study population. The CCM index 
however was designed to look at mortality risk and includes co-morbidities 
which predict mortality. However, despite its name, the CCM does not 
provide an overall assessment of co-morbidity burden. Those with advanced 
cancer attract a higher CCM score due to the cancer itself, so the cancer 
diagnosis may “overshadow” other co-morbidities in the rating.  Bond (2006) 
used the APACHE II, which can provide useful information about illness 
burden. However, the required variables (such as arterial blood gas) aren’t 
readily available for cancer patients in a ward setting, making APACHE II ill-
suited to describing the illness burden of admitted cancer patients, outside 
of a critical care setting. 
 
Optimal description of participant characteristics and burden of disease has 
been advocated in relation to delirium research in hospitalised patients in 
general [1], and is equally valid for cancer patients in the acute setting. 
Adherence to contemporary consensus statements [61] regarding the 
reporting of patient characteristics would aid interpretation of results and 
generalisability in the cancer and supportive care setting. Reporting of 
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characteristics relevant to prognosis and disease trajectories [62] would 
assist interpretation of study findings. Consistency of reporting would also 
enable future systematic reviews and meta-analysis.  Standardised reporting 
of patient characteristics, and the use of assessment tools and delirium 
reference standards where possible will improve epidemiological studies of 
delirium in this setting. 
 
1.5.10 Limitations 
There are limitations to our review related to the methodology of the original 
studies, as discussed above. In order to prevent and treat delirium it is 
necessary to better understand which bedside clinical tools are best suited 
to the adult oncology population. Important questions include which tools 
translate well from aged care and stand-alone inpatient palliative care 
settings, which are most suitable for patients, carers and staff, and which 
reference standards are most appropriate? Establishing a methodical 
approach to the detection of delirium in clinical and research settings is a 
prerequisite to determining the incidence, prevalence and reversibility of 
delirium in this setting. Maintaining a clear accountability for the validation 
and purpose of the tool, and its use for clinical screening or as a diagnostic 
reference standard, is essential.  
 
1.6.0 CONCLUSION 
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This scoping review identified knowledge gaps from which new hypotheses 
for future investigation have been generated. In terms of knowledge 
translation, important issues arising from this review have been noted 
including the need to systematically report patient characteristics and clinical 
setting, to select delirium detection tools appropriate to the setting and 
study methodology, to use reproducible methods of patient selection with 
accurate, reproducible tools for diagnostic assignment, to describe patient 
characteristics within a methodology which allows interpretation of incidence 
and prevalence data for the index population. Our results indicate that a 
determination of the incidence, prevalence, and reversibility of delirium in the 
in-patient cancer population is both lacking and overdue. Addressing these 
knowledge gaps will help to provide a more robust evidence base to inform 
ongoing efforts for effective prevention, detection and management of 
delirium in the inpatient oncology setting. 
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CHAPTER 2. SQID, THE SINGLE QUESTION IN DELIRIUM; HOW 
USEFUL IS A SINGLE QUESTION IN DETECTING DELIRIUM IN 
HOSPITALISED CANCER PATIENTS? 
The Single Question in Delirium (SQiD) is tested against psychiatrist 
diagnosis based on clinical interview using Diagnostic and Statistics Manual 
(DSM) criteria. 
 
2.0  ABSTRACT 
BACKGROUND: Delirium has notable negative impacts and is an important diagnosis for 
hospitalised cancer patients. Effective screening tools are available however delirium 
detection is frequently delayed or missed, compounding poor outcomes for patients, their 
carers and staff. Delirium detection tools have been tested in other settings, but the uptake 
of screening in the setting of admitted, adult oncology patients is not well established.  
 
OBJECTIVE: We aim to determine the utility of a ‘Single Question in Delirium’ (SQiD) to 
detect delirium in this setting, comparing its performance against the reference standard of 
psychiatrist interview.  
 
METHODS: Patients admitted to the oncology wards of two comprehensive cancer centres 
in Sydney, Australia were prospectively screened. The SQiD: “Do you feel that [patient's 
name] has been more confused lately?” was put to the available carer or family member by 
ward staff. Interview by consultant psychiatrist and the short CAM were conducted, with 
assessors blinded to other results. The primary endpoint was negative predictive value (NPV) 
of the SQiD versus psychiatrist diagnosis. Secondary endpoints included: NPV of the CAM 
versus the psychiatrist interview, sensitivity, specificity and Cohen’s Kappa coefficient.  
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RESULTS: Recruitment occurred between May 2012 and July 2015: 120 patients had both 
the SQiD plus CAM tests and 71 had the SQiD index tool and psychiatrist interview. Median 
age was 67 years, 41% were female. In total, 65% were admitted under medical oncology, 
with a median length of hospital stay of 12 days; [interquartile range (IQR) 14]. Major cancer 
types were: lung 21%; breast 12%; and prostate 10%. Overall, 73% of participants had 
stage 4 cancer, and 9% had cerebral metastases, and 83% of admissions were for symptom 
management or investigations. The SQiD informant and patient cohabited in 54% of cases. 
Median Karnofsky performance status was 60 (IQR 50-70). The NPV of the SQiD versus 
psychiatrist interview (diagnostic standard) was 74 (95%CI 66.17 - 80.55); NPV of the CAM 
was 71 (95%CI 65.96 -75.90). Kappa correlation of SQiD versus psychiatrist diagnosis was 
0.34 (95%CI 0.11-0.58). Kappa correlation of CAM versus psychiatrist diagnosis was 0.31 
(95%CI 0.11-0.52). Sensitivity of the SQiD was 44% (23.19 - 65.51) and specificity was 88% 
(74.37 - 96.02). The CAM measured against psychiatrist interview had sensitivity and 
specificity of 26% (10.23 - 48.41) and 100 (91.59 - 100) respectively. Of the 16 patients with 
hypoactive delirium, 6 were identified on SQiD, the CAM identified one. The SQiD was 
acceptable to carers and patients, fostering discussion about delirium symptoms among 
both carers and staff.  
CONCLUSION: The SQiD, administered by ward clinical staff, was feasible to use on a busy 
oncology setting, and demonstrates favourable psychometric properties. The SQiD has 
potential to set a new standard of care as a delirium screening tool for hospitalised cancer 
patients.  
 
2.1.0     BACKGROUND AND AIM 
Delirium is a syndrome defined in terms of neuro-cognitive features and level of arousal, with 
inattention a salient feature.[3] It is common, and often reversible but delirium diagnosis is 
frequently missed. To improve detection, screening for delirium has been advocated in 
hospitalised patients [4], however the uptake of routine screening in oncology in-patient 
settings is unknown. The selection of a delirium screening tool will depend on clinical utility 
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and the tool must be suited to the setting in which it will be used.[1] Secondly, the choice of 
an accurate and reproducible reference standard is important in a validation study, and the 
study design must minimise bias due to the order and timing of application of study 
instruments.[30] In designing a study for testing a new tool in delirium detection, we aimed 
to account for these important issues. 
 
An ideal tool for detecting delirium in the clinical oncology setting would have good 
sensitivity, specificity, and negative predictive value (NPV) for all sub-types of delirium, 
including hypoactive delirium, which is often difficult to detect.[63] The tool would be simple 
and quick to administer, conferring the least possible burden on the patient and family or 
carers, while providing timely, accurate information. Staff training would be pragmatic and 
administration requirements achievable in a busy clinical setting, to promote regular and 
sustained use, including after hours.  
 
Validated screening tools for detecting delirium in hospitalised patients have been reviewed 
elsewhere [15, 16], however many require specific training, and all take at least a few 
minutes to administer. Furthermore, only a few validated detection tools have been tested in 
oncology in-patients; most delirium detection tools tested for patients with cancer have 
been assessed in “stand-alone” palliative care in-patient units. At the time of study design 
three tools, the Mini Mental State Examination (MMSE), Memorial Delirium Assessment 
Scale (MDAS) and the Confusion Assessment Method (CAM) [53], were most commonly 
reported in studies in patients with cancer. Subsequently, the Nursing Delirium Rating Scale 
(Nu-DESC) [26] and “4 A’s test” (4AT) [54] have been favourably tested for delirium 
screening in “stand alone” palliative care settings.  
 
As discussed in chapter one all delirium tools have some methodological issues and the 
choice of detection tool must be tailored to the clinical and or study setting. It is important 
however to note the MMSE is not regarded as an adequate delirium screening tool.[60] The 
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MDAS, although well documented in acute-hospital in-patient palliative care settings, was 
developed to rate the severity of delirium, and therefore is not considered here as a delirium 
screening tool.[16]  
 
The CAM is the most widely used delirium detection tool in clinical and research settings. 
The use of the CAM as a delirium screening tool as well as diagnostic tool or reference 
standard is supported. When applied by staff well trained in its administration, the CAM 
achieves overall sensitivity of 94% (95% confidence interval [CI] 91– 97%), and specificity of 
89% (95% CI 85–94%)[58]. However, the CAM is not simple to use, and relies heavily on the 
skill and training of the operator[53], making it impractical in some clinical settings, 
especially those with high staff turnover. In addition, the CAM must be accompanied by a 
test of cognition such as the mini-cog,[58, 64] which although relatively brief to administer, 
adds to the total time and complexity of screening with the CAM.[65] 
 
Brief delirium detection tests have been developed and tested in settings such as aged 
care[66] and emergency medicine[67]. The 4AT[56], the brief CAM[58] and the “Recognizing 
acute delirium as part of your routine” (RADAR)[68, 69] have all been recently tested for 
delirium screening in these settings. Given the salience of inattention in delirium diagnosis, 
as well as the favourable training and administration requirements, several studies have 
focused on bedside tests of attention for delirium screening.[65] Outside of 
oncology/palliative care settings, tests of global attentiveness, such as a 3-5 minute 
discussion between clinician and patient, have been shown to have good psychometric 
properties, when administered by geriatricians.[16] Some authors have suggested the 
combination of a highly sensitive tool, such as a test of attention or altered level of 
consciousness, followed by a highly specific tool in settings such as emergency 
medicine.[67] Therefore, maximising sensitivity or specificity, but not necessarily for the one 
tool, may be of relevance when determining the qualities of a novel screening tool, as 
combination with a second tool may leverage complimentary properties of each tool. The 
reference standard used for case ascertainment is critical when testing a novel delirium 
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screening tool, and should ideally use an accepted diagnostic classification system such as 
the the International Classification of Diseases version 10 (ICD-10)[70] or Diagnostic and 
Statistical Manual of Mental Disorders (DSM) (various editions).[1, 2, 71] 
 
We hypothesised that a pragmatic single question tool, that can be administered as part of 
routine clinical history taking, and is supported by usual education that is part of medical 
and nursing training, would be advantageous in the oncology setting. We therefore 
previously devised and performed feasibility testing for the SQiD, a single-question, 
informant-response tool for detecting delirium.[34] The aim of this present study is to test 
the utility of the SQiD in an oncology inpatient setting, comparing its performance against 
the reference standard of psychiatrist interview. 
  
2.2.0 METHODS 
2.1.1 Study Design and Setting 
This is a prospective, cross-sectional, observational study to evaluate the usability of the 
SQiD as a clinical tool for detecting delirium in hospitalised, oncology patients. Patients 
were recruited from the in-patient oncology wards of two comprehensive cancer centres in 
Sydney, Australia: The Prince of Wales and Concord Repatriation General Hospital. Baseline 
demographics, including gender, age, admitting team, cancer stage and performance 
status, were recorded for the sample population and the background population. The 
background population was defined as all patients admitted for more than one night during 
the study period. Usual ward staff undertook training for the CAM and SQiD.  
 
2.1.2  Human Research and Ethics approval, Participant Recruitment, 
Consent and Study Withdrawal 
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Low/negligible risk (LNR) human research and ethics approval was gained from the South-
Eastern Sydney Local Health District Human Research Ethics Committee (approval number 
LNR 11/156).  An in-patient census was generated daily to alert the study team to 
admissions under the relevant admitting teams (medical oncology, radiation oncology or 
cancer palliative care). The team member screening patients (a year 3 medical student and 
one of two consultant physicians) prompted administration of SQiD by ward staff. 
Eligible patients were included regardless of cancer primary site, or stage of disease 
included patients were adults on a dedicated oncology ward of participating hospitals. In 
order to mitigate bias, consecutive admissions on nominated recruitment days were 
targeted for inclusion. At site two, recruitment occurred on Monday to Wednesday due to 
research staff availability.  
 
Patients admitted for a same day or single overnight stay or for chemotherapy or 
radiotherapy only, those who were comatose, those judged by ward staff to be in the very 
last days of life, or those with inadequate English fluency for consent and CAM 
administration, were excluded. Other exclusion criteria were the inability to give informed 
consent, no family/friend identified to give consent on behalf of the patient, or no 
family/friend identified to be the SQiD informant. 
 
All attending medical oncology, radiation oncology and palliative care physicians at the 
participating institutions agreed for their patients to have the SQiD and CAM administered 
as part of usual care. Consent for the interview was specifically sought from patient or proxy 
prior to approach by the psychiatrist, but after SQiD and CAM administration. If the patient 
was unable to give informed consent, consent was sought from the appropriate substitute 
decision maker and documented accordingly. Patient and family/friend were able to 
withdraw from the study at any time. Consent was sought from withdrawing patients for use 
of data collected up to the point of study withdrawal, and where consent was granted, all 
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data of withdrawn subjects were included for analyses. Only SQiD and CAM scores for 
consented patients were analysed. 
 
Staff were directed to choose someone in close contact with the patient as the SQiD 
informant. In most instances this was the usual person (relative, friend or carer) to whom 
health care professionals would turn in the course of clinical care when a colateral history or 
further information regarding the patient’s well-being and progress was required.  
 
2.1.3 Sequence and administration of delirium screening tools and 
reference standard used for case ascertainment 
Two delirium screening tools, the SQiD and the CAM were sequentially administered (See 
Figure 2.1), followed by the diagnostic reference standard (DSM based clinical interview with 
a consultant liaison psychiatrist). All patients included in the primary analysis received the 
reference standard. Study flow was designed to mitigate training or exposure bias of the 
informant, and administration of the SQiD always preceded the CAM; the psychiatrist 
interview was performed last in the sequence. As the SQiD and CAM were accepted by 
attending physicians and the Human Research Ethics Committee (Australian equivalent for 
an ethical review board) as consistent with usual clinical assessments, a waiver of consent 
was allowed. Consent for use of data and assessment by a psychiatrist (as this is not usual 
care) was obtained subsequent to the screening tools (SQiD and CAM), but prior to the 
reference standard (psychiatrist interview). The SQiD and CAM were administered by ward 
clinical staff usually involved in the care of patients of participating oncology wards, this 
included ward nursing and medical staff, consulting teams (palliative care) or medical 
students. The CAM, SQiD and psychiatrist interview were performed by a different assessor 
and all were blinded to the results of other tests. The psychiatrists, although blinded to 
screening test results, had access to the medical record, as would usually occur during the 
course of a clinical consultation.   
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2.1.4 Administration of the SQiD  
The SQiD was framed: “Do you feel that [patient’s name] has been more confused lately?” A 
dichotomous response of yes or no was recorded. The SQiD was preferentially administered 
in person but, if necessary, could be administered over the phone. Administering ward staff 
were not constrained in answering questions from patients, family or other staff and 
students, prompted by the SQiD; rather this was seen as an opportunity for patient/carer 
education. Staff made it clear that all admitted patients were being approached, rather than 
patients felt to be at particular risk of delirium.  
 
2.1.5 Training for SQiD administration 
There was no specific training for the SQiD. A one-hour, in-service education session on 
delirium was delivered by the investigators at each site (MBS and JL) on two occasions to 
cover shift changes. Administering clinicians were informed this was a tool to identify 
delirium and given a paper prompt with the SQiD wording on it. The SQiD question was 
always asked verbally by a clinician, the question was not administered as a questionnaire.  
 
2.1.6 Confusion Assessment Method training and administration 
The Short CAM [72] was the CAM version utilised throughout this study.  The CAM was 
tested in parallel to the SQiD and was employed as a comparator delirium screening tool. 
The CAM is an operationalised diagnostic algorithm focusing on five diagnostic criteria: 
acute onset, inattention, disorganised thinking, altered level of consciousness and 
disorientation.[58] All staff were provided with the Short CAM training manual instructions 
and tasked with following them.[72] At site one CAM training was undertaken by two senior 
palliative care nurses who were to administer the tool, and consisted of two training 
sessions of approximately 40-minutes were undertaken with an experienced clinical nurse 
consultant in aged care, who assesses for delirium all people aged over 65 years admitted to 
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the Emergency Department at that site. At the second site, two clinical psychologists 
received two training sessions in the use of the CAM by an aged care clinical nurse 
consultant who uses the CAM in clinical practice daily. The Mini-Cog [64] was used as the 
short cognitive test pre-requisite to CAM administration. Formal inter-rater reliability was not 
tested. 
 
2.1.7 Participant Interview by Consultant Liaison Psychiatrist 
An accredited consultant liaison psychiatrist (psychosomatic medicine psychiatrist) 
assessed each patient in a brief interview, according to the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) [2, 71] classification.  Presence or absence of delirium 
was recorded by the psychiatrist who noted delirium motoric subtype (hyperactive, 
hypoactive or mixed). If another diagnosis was identified, the primary team were notified 
with the consent of the participant. During the study period, there was a change in the DSM, 
from DSM IV TR[71] to DSM V[2], and throughout the study the contemporaneous edition 
was used. Two psychiatrists were involved at site 1, and one at site 2. Our aim was for the 
psychiatric interview to be performed within approximately 24hrs of the SQiD and CAM.  
 
2.1.8 Demographic variables  
Age; gender; cancer diagnosis; stage of disease; site of metastases; Eastern 
Clinical Oncology Group (ECOG) performance status; Australian Karnofsky 
Performance Status (AKPS); and number of days since admission were 
recorded. Mean, standard deviation (SD), median and interquartile range 
(IQR) were calculated for continuous variables. Information about the 
informant included their relationship to the patient and informant participant 
co-habitation.  
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2.1.9 Outcome measures 
The primary outcome was the negative predictive value (NPV) of the SQiD versus 
psychiatrist interview. Secondary outcome measures included: NPV of the CAM versus the 
psychiatrist interview and comparison of the NPV of the SQiD and CAM in relation to 
psychiatrist interview. Positive predictive values, sensitivity specificity and kappa correlation 
of these tools was also calculated. NPV was chosen as minimising false negatives was 
judged to be a salient feature of a screening tool. 
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2.1.10 Statistical analysis 
Agreement between tests was measured by estimating sensitivities, specificities, positive 
predictive and negative predictive values, as well as Cohen’s kappa statistic (kappa) using 
the contemporaneous DSM diagnosis as the diagnostic reference standard. Sensitivity 
represents the proportion of patients with delirium who were correctly identified using a test 
(SQiD and CAM).[73] Specificity represents the proportion of patients without delirium who 
were correctly identified using a test.[73] Positive predictive value (PPV) represents a 
proportion of patients with delirium identified using a test, who are correctly diagnosed.[74] 
Negative predictive value represents a proportion of patients without delirium identified 
using a test, who are correctly diagnosed. The kappa statistic represents the proportion 
agreement corrected for chance.[75] Kappa values above 0.75 denote excellent agreement, 
0.40 to 0.75 fair to good agreement and below 0.40 poor agreement. Data management and 
analysis were undertaken using SAS software, version 9.3.[76] 
 
A maximum sample size of 133 was calculated to detect 50% sensitivity (“worst case” 
scenario) with 20% precision, with an alpha of 5% and an assumed delirium prevalence of 
18%. A sample size of 194 was needed to achieve 90% sensitivity with 5% precision.   
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2.3.0    RESULTS 
Recruitment occurred between 7th April 2012 – 8th May 2015 at site one, 
and from the 19th of March 2014 – 2nd of September 2015 at site two. Figure 
2.2 outlines total number of patients admitted at both sites during the study 
period, eligible participants and numbers who consented. Overall, 1195 were 
eligible for study inclusion on the basis of ward, admitting specialist, and 
length of stay; 139 were excluded on other study criteria, 243 did not 
progress from initial index testing to consent (largely due to staffing 
constraints), and an additional 379 were transferred or discharged prior to 
approach; seven patients declined to participate or withdrew consent. A 
further 287 patients were not approached due to staffing constraints.   
  
51 
Figure 2.1 Order of administration of tests, consent and diagnostic 
reference standard 
Eligible ward admissions n=1175 
Single Question in Delirium (SQiD) n=343
Confusion Assessment Method (CAM) n= 269
Interview with Consultant Liaison Psychiatrist n=71*
Consent n=140 
*excludes 4 patients with missing SQiD data
Primary analysis n= 71
Secondary analysis n=120
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Figure 2.2 Recruitment Flow Diagram 
Eligibility for inclusion: admission to cancer ward under the care of Medical 
Oncology, Radiation Oncology, Palliative Medicine, age >18yrs. 
Exclusion: admission to non-oncology wards, overnight stay, admission 
indication chemotherapy only or radiation treatment only.  
 
 
 Consent occurred prior to psychiatrist interview and following SQiD and CAM 
 Excludes all data from 5 patients with missing consent.  
 Includes 4 patients with consent but missing SQiD. 
 
In total, 343 patients had the SQiD test administered, of those 170 went on to consent. 
Overall, 269 completed the CAM and 140 patients completing both SQiD and CAM 
progressed to consent to psychiatric interview. Forty three patients were excluded due to 
lack of English sufficient for consent and delirium tests. SQiD data was missing for four 
consenting patients who completed CAM and psychiatrist interview. Data from 71 
Site 1:  7/4/2012 – 8/5/2015 
 
Site 2:    19/3/2014 – 2/9/2015 
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consenting patients who completed both SQiD and psychiatrist interview was available for 
primary analysis. In total, 120 patients who went on to consent, completed SQiD and CAM 
tests, providing data for secondary analysis. Five consent forms could not be located and 
data for these patients were excluded from the analysis. 
The median age across all consenting participants was 68 years (range 22-89, IQR 19, 
n=120) and of these, 49 (41%) were female. Major cancer types were: lung 23 (19%); breast 
13 (11%); and prostate 11 (9%). Of these 120 patients, 80 (67%) had stage IV cancer, and 
cerebral metastases were present in 8 (7%). In total, 88 (73%) of 120 participants admissions 
were for symptom management.  The SQiD respondent and the patient resided together for 
68 (57%) participants. Median length of hospital stay was 13 days (n=71, range 2-49, IQR 
14). Median Australian Karnofsky performance status was 60 (IQR 50 – 70), with a range 
from 20-100. Combined demographic data across both sites are presented in Table 2.1. 
Difference between the study participants and the source population reached statistical 
significance in regard to older age, and longer lengths of hospital admission (length of stay). 
The study participants (n=120) were 49% female while the source population were 53% 
female, this was a non-statistically significant difference. Age in years of participants was 67 
(SD 11.5) versus 63 (SD15) (p=0.008 t-test), and median length of stay in days 13 (SD 10) 
versus 8 (SD 9) (p=0.001 t-test), female gender 53% versus 45.5% (p=0.22 Chi-square test) 
respectively. Data comparing recruited versus non-recruited patients are presented in Table 
2.2. The median time difference between administration of the SQiD and the psychiatrist 
interview was 26hrs, and 23hrs between the CAM and psychiatrist interview (see Table 2.3.) 
Table 2.1 Demographic information relating to patients included in 
secondary analysis 
  
n valid = 120 
Gender N* %* 
Female 49 40.8 
Male 59 49.2 
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Admitting team 
  
Medical Oncology 78 65.0 
Radiation Oncology 21 17.5 
Palliative Care 9 7.5 
   
Admission indication 
  
Symptom 
Management 88 73.3 
Tumour type 
  
Lung 23 19.2 
Gastric & other 
Upper GI 15 13.5 
Breast 13 10.8 
Prostate 11 9.2 
Colon 9 7.5 
Other 37 30.8 
 
Tumour stage 
  
Stage I 1 0.8 
Stage II 9 7.5 
Stage III 17 14.2 
Stage IV 80 66.7 
*Numbers do not add up to 100% due to missing data | IQR interquartile range 
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Site of 
Metastasis 
  
No 
documented 
metastasis  29 24.2 
Bone 24 20.0 
Liver 13 10.8 
Lung 8 6.7 
Brain  8 6.7 
Other 1 0.8 
Unknown/missi
ng 17 14.2 
 
ECOG Score 
  
0 3 2.5 
1 25 20.8 
2 35 29.2 
3 32 26.7 
4 2 1.7 
Unknown/missi
ng 23 19.2 
   
Australian 
Karnofsky Score 
  
100 1 0.8 
90 7 5.8 
80 16 13.3 
70 24 20.0 
60 18 15.0 
50 17 14.2 
40 5 4.2 
56 
30 5 4.2 
20 2 1.7 
Unknown/missi
ng 25 20.8 
Median 60           IQR  50 – 75           Range 20-100 
    
 
SQiD informant cohabitation with patient 
No 51 42.5 
Yes   68 56.7 
 
   *Numbers do not add up to 100% due to missing data | IQR interquartile range 
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Table 2.2 Comparison of characteristics of participants versus background population; gender and continuous variables 
 
n valid 
Participants 
120 
Background population 
2352 
Test of difference 
Female 49% 53% p=0.223 (Chi-square test) 
Mean Age, SD (range) 
 
67 years, 13 (22-89) 
108 
63, 15 (18-102) 
 
p=0.008* (t-test) 
Mean Length of stay (SD) 
 
13.2 (10) days 
71 
8 (9) days 
 
p=0.008* (t-test) 
 
Median Length of stay, SD, 
IQR, (Range) 
12 days, 14 (2-49 days) 
71 
   5 days, 7 (0-127) 
 
P<0.001* (t-test) 
 
Background population is all eligible admissions with > one overnight stay 
                                                                                                                                                      *Statistically significant  
n valid Number Valid| SD Standard Deviation | IQR Interquartile Range  
  
58 
Table 2.3. Timing of administration of tests 
 
   n valid 
 
Mean 
 
SD 
 
Median 
 
IQR 
 
Range 
 
SQID - PD time 
difference (hours)*     63 
50 56 26 51 0.2 - 219 
SQID - CAM time 
difference (hours)*   109 
22.5 34 18 22 0 - 208 
CAM - PD time 
difference (hours)*     58 
42.5 48 23 47 0.75 - 169 
 
 
* Excludes 2 patients with incorrect dates 
   PD Psychiatric Diagnosis | n valid Number Valid| SD Standard Deviation | IQR Interquartile Range  
   SQiD Single Question in Delirium | CAM Short Confusion Assessment Method | PD Psychiatrist DSM interview 
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The primary endpoint of NPV of the SQiD compared to psychiatrist interview was 72.22% (95%CI 
64.61- 78.74; n=71). The NPV of CAM was 71.19% (65.96 - 75.90; n=65). The Kappa correlation value 
for SQiD and CAM versus psychiatrist interview was 0.36 (95% CI 0.14 - 0.58) and 0.31 (95% CI 0.11 
- 0.52) respectively. The sensitivity of the SQiD was 44.44% (25.48 - 64.67) and the specificity was 
88.64% (75.44 – 96.21). The CAM had sensitivity and specificity of 26.09% (10.23 - 48.41) and 100% 
(91.59 - 100) respectively. The diagnosis of delirium based on psychiatrist interview was made in 35% 
of those interviewed (4/71 hyperactive, 17/71 hypoactive, 6/71 mixed). On the basis of the SQiD, 
17/71 (23.1%) participants were delirium positive compared to 9.2% (6/65) by the CAM. Of the 17 
patients with hypoactive delirium diagnosed by psychiatrist interview, the SQiD identified six of the 
cases, while the CAM identified one. Primary and secondary endpoints are presented in Table 2.4. 
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Table 2.4.     Agreement of measures comparing different methods for detecting delirium    
Comparison 
n valid 
 
True  
+ 
False 
+ 
False  
- 
True  
- 
Prevalence 
 (tool) 
Prevalence 
(tool) 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Kappa 
SQiD vs PD 
71 
12 5 15 39 23.94%  
(SQiD) 
38.03%  
(PD) 
44.44  
(25.48 - 64.67) 
88.64  
(75.44 - 96.21) 
70.59  
(48.72 - 85.84) 
72.22  
(64.61 - 78.74) 
0.36  
(0.14 - 
0.58) 
SQiD vs PD 
65 
10 5 13 37 23.08%  
(SQiD) 
35.38%  
(PD) 
43.48  
(23.19 - 65.51) 
88.10  
(74.37 - 96.02) 
66.67  
(43.72 - 83.74) 
74.00  
(66.17 - 80.55) 
0.34  
(0.11 - 
0.58) 
CAM vs PD 
65 
6 0 17 42 9.23%  
(CAM) 
35.38%  
(PD) 
26.09  
(10.23 - 48.41) 
100  
(91.59 - 100) 
100  
(NA) 
71.19  
(65.96 -75.90) 
0.31  
(0.11 - 
0.52) 
SQiD vs CAM 
65 
5 10 1 49 23.08%  
(SQiD) 
9.23% 
(CAM) 
83.33  
(35.88 - 99.58) 
83.05  
(71.03 - 91.56) 
33.33  
(20.39 - 49.39) 
98.00  
(89.08 - 99.66) 
0.40  
(0.13 - 
0.67) 
SQiD vs CAM 9 28 2 81 30.83%  9.17%  81.82  74.31  24.32  97.59  0.27  
61 
120 (SQiD) (CAM) (48.22 - 97.72) (65.06 - 82.20) (17.38 - 32.93) (92.00 - 99.30) (0.11 - 
0.44) 
PPV positive predictive value | NPV negative predictive value | Kappa Cohen’s kappa correlation 
SQiD Single Question in Delirium | CAM Short Confusion Assessment Method | PD Psychiatrist DSM interview 
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2.4.0 DISCUSSION 
The primary and secondary outcome measures demonstrated utility of the SQiD in the target setting. 
The primary study endpoint showed the SQiD is comparable with the CAM in terms of NPV against a 
diagnostic reference standard. Secondary endpoints showed a moderate kappa correlation of both 
SQiD and CAM in relation to the reference standard. The CAM had a better PPV however a low 
sensitivity. The SQiD had better sensitivity than the CAM and although not formally tested, the 
simplicity of the SQiD was greeted by enthusiasm by clinical staff.  
Methodological strengths of our study include a clear description of patient characteristics and setting 
that mitigated bias due to case ascertainment method and training bias due to study flow; use of an 
accurate and reproducible reference standard with a clear description reference-rater training was 
also a strength.  This was a pragmatic, ‘real world’ study. Ward clinical staff administered the study 
tools, which was a strength from the point of view of supporting translation from research to clinical 
implementation but resulted in decreased recruitment due to competing demands on clinical staff. 
Study strengths also relate to the index tool which was developed and tested by clinicians in the 
target setting. The SQiD is simple and provides a pragmatic approach to support uptake.  
The ability to detect hypoactive motoric sub-types is important in delirium screening tools. In this 
respect, the SQiD demonstrated a trend to better performance compared to the CAM, however given 
the small numbers in each motoric sub-group, this observation needs to be interpreted with caution.  
Limitations of our study relate to a non-consecutive sample and exclusion of some patient groups, 
this is relevant to rates of delirium detection in our sample. The incidence and prevalence of delirium 
in cancer in-patient cohorts is not well established, with most studies assessing delirium in the 
hospital setting, targeting older patients across all wards or cancer patients referred for palliative care 
or liaison psychiatry consultation. Delirium prevalence rates in oncology wards of acute hospitals and 
cancer care centres ranging from 16.5-33% have been reported, however these must be interpreted 
in the context of study quality (see chapter 1). Prevalence of 18-35% have been reported in other 
hospital inpatients [77], and together these data provide a context to help interpret our study findings 
of a  rate of delirium of 35%.  This rate must also be interpreted in the context of recruitment bias 
towards longer length of stay and greater age in study participants versus eligible patients. 
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A further limitation was that SQiD administration appeared to be dependent on prompting by senior 
staff, making recruitment subject to variation due to competing demands and staffing.  The time 
between SQiD, CAM and psychiatric interview was also generally longer than anticipated in the 
protocol. This can have implications for diagnosis as delirium can fluctuate with time. 
Although we attempted CAM training for study staff to the maximum possible within constraints of our 
clinical context, it fell short of the recommended training, and we were unable to achieve the 
sensitivity and specificity reported elsewhere after stringent CAM assessor training.[58]  
Finally, a number of patients were excluded due to lack of English fluency (n=43), therefore 
conclusions about utility of the SQiD in patients across diverse cultural and linguistic backgrounds 
remains untested. Similarly, the SQiD may be of lower utility for patients who live alone or have limited 
contact with other people. Nevertheless, of 120 patients in our study, only five were excluded due to 
not having a person available to answer the SQiD question. In settings such as residential aged care a 
different informant might be considered such as nursing staff, but this would require formal testing 
and is outside the scope of our study. 
 
2.4.1  Implications for training and practice 
The SQiD supports clinician training by demonstrating the investment of clinician time in delirium 
assessment and further, its use may increase the motivation of staff to maintain their clinical 
knowledge when families ask questions in response to the SQiD. Engaging carers and staff in 
conversations regarding a patient’s cognitive function has the potential to promote staff self-efficacy 
and reinforces clinical skills in keeping with principles of adult learning and professional development. 
The SQiD may engage nurses, medical staff, carers and/or patients in discussion regarding the 
components of syndromal delirium. The use of the SQiD by clinical staff may reinforce the concept 
that delirium is an important medical issue for staff, patients and family/carers.  
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2.4.2 Implications for research 
Other work has compared short tests of cognition or attention. One study tested single questions in 
other settings (e.g. gerontology[66]) and another compared the SQiD to a novel test [78]. Lees et al 
used a single informant question directed to staff [79], however, to our knowledge, having a clinician 
directly approach the main carer with a conversational approach and a simple question regarding 
recent changes in cognition, has not been previously evaluated. Future research questions may focus 
on the content of the discussion that ensues following administration of the SQiD, and whether 
indirect communication via a questionnaire is as effective as direct communication either in person or 
via telephone. 
 
The present study supports the hypothesis that the SQiD is comparable to the CAM in terms of 
identifying patients with syndromic delirium in the target setting. As discussed, the combination of a 
screening tool with high sensitivity followed by one with high specificity may be a useful approach to 
screening and could be addressed in future studies. Since inception of this study other short and brief 
tools have been published in the peer review literature, including the 4AT [56] and more recently the 
delirium RADAR [69]. These tools are promising either alone or in combination, however they may not 
have the same qualities of engaging carers and staff that is possible with the SQiD.  
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2.5.0 CONCLUSION  
The SQiD had NPV comparable to the CAM when used with a pragmatic level of training in our clinical 
setting. The SQiD has favourable psychometric properties; on face value it is feasible and pragmatic 
for staff, acceptable to carers and patients and engages staff, family and carers in a shared goal. The 
SQiD has potential to set a new standard of care for oncology patients. 
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THESIS OVERVIEW 
Delirium has been established as an important clinical syndrome associated with poor outcomes for 
patients, carers and staff.  Risk of delirium increases with illness complexity and severity, placing 
cancer patients at risk of the negative impacts of this syndrome. 
 
There is paucity of population-based data to inform our understanding of delirium in acute oncology 
settings. Our scoping review identified few published studies, and most of these had significant 
methodological limitations. What can be understood from the studies which have been conducted is 
that a variety tools have been used for delirium detection; the most common reference standards 
identified were ICD-10 and DSM criteria and the CAM. In relation to the CAM however our we found it 
was not always appropriately used. Operator training was a prominent issue and the need for 
intensive operator training was an important consideration. 
 
Our review supports the hypothesis that delirium is common in hospitalised cancer patients however 
the reviewed studies were heterogeneous in design, preventing calculation of a pooled prevalence.  
Five studies presented incidence rates, ranging from 3.5% to 45% of all reported admissions. Studies 
found prevalence ranging from 18-33% in the oncology setting, 19-57% in the older patient setting, 
and 42-71% in the palliative care setting. One study in older patients across 120 hospital wards in 
Italy, found a point prevalence of 19% using the 4AT, a validated screening tool. 
 
 
The evidence available suggests that delirium is often reversible, even towards the end of life. Only 
two of the reviewed studies evaluated reversibility, reporting rates of 26% and 49%. However, both 
studies were in the acute palliative care setting and had major methodological flaws. A further study in 
the older cancer patient setting reported reversibility, however the methodology was only briefly 
described. These results need to be interpreted with caution. Accurate data relating to reversibility in 
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the acute oncology setting are required.   
 
An important finding was the absence of diagnostic reference standards in many studies. We would 
support clear distinction between a delirium screening tool and a diagnostic reference standard as an 
essential methodological issue. Many studies did not make this distinction and the delirium detection 
tools were often not evidence based.  
 
To take delirium care forward in the oncology setting, pragmatic approaches to delirium detection are 
required. More importantly, suitable tools for use in clinical practice are critical. In a clinically based 
research setting, a delirium detection tool must be pragmatic and appropriate for the setting and 
study design. A multi-centre, large, point prevalence study requires a simple, brief tool that can be 
easily applied in the relevant clinical setting. However, a diagnostic reference standard is optimal 
when evaluating incidence and prevalence of delirium. These characteristics are at times competing, 
therefore a clear rationale for the use of a screening tool, versus a diagnostic standard is required. If 
use of a diagnostic reference standard is not feasible (e.g. in a large point prevalence study), use of a 
delirium screening tool validated in the population is essential. Importantly, a study evaluating a novel 
tool must compare the new tool to an established diagnostic reference standard, such as the DSM or 
ICD criteria, for validation purposes.  
 
The major aim of this thesis was to improve delirium detection in oncology clinical practice, by 
developing a simple tool for delirium detection suitable for use in the acute oncology in-patient 
setting. Existing delirium screening tools available at the time were complex to apply, and required 
administrator training. The SQiD was developed as a single item tool, taking only a few minutes to 
administer, so that it could be incorporated into routine clinical practice. It was devised to be applied 
by clinicians, with no specific aged care or psychiatric training and to require no specific administrator 
training. . The SQiD was intended to reinforce standard clinical training of nursing and junior medical 
staff, and support staff and carer self-efficacy by encouraging active participation in delirium 
detection.  
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The second important aspect of the SQiD is the utilisation of informant observations. This was 
intended to start a conversation between carers and staff about aspects of delirium and to emphasise 
to patients, staff and carers the importance of delirium as a clinical syndrome. This is beyond the 
scope of the current study but further research is required to determine the content of conversations 
prompted by the SQiD and its utility in supporting staff and carer learning about delirium and whether 
use of the SQiD is appropriate across clinical disciplines.  
 
In our evaluation the SQiD had good negative predictive value (72%) and fair agreement (kappa 0.36) 
when compared to a robust diagnostic reference standard. These findings provide a rationale for 
further psychometric testing of the SQiD within the inpatient oncology setting. Evaluation in other 
inpatient and outpatient settings would provide insights into its utility elsewhere. Another option for 
further research is using the SQiD together with a high sensitivity tool, to evaluate the added benefit of 
combining a high sensitivity and a high specificity tool.  
 
There remain important gaps in understanding the pattern, risks and reversibility for delirium in the in-
patient oncology setting, and this will be fundamental to raising delirium as an important clinical issue 
in oncology care. The SQiD offers a clinically pragmatic delirium screening tool, which warrants more 
extensive psychometric testing and exploration of approaches for implementation to determine if the 
SQiD has the potential to become standard of care for delirium detection and to open conversations 
about altered mental status in the oncology setting.  
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